title: Genotype A1/A2 associated with neuroleptic malignant syndrome.
authors: M
authors: M
authors: Del Tacca
authors: L
authors: L
authors: Lattanzi
authors: M
authors: M
authors: Lastella
authors: A
authors: A
authors: Di Paolo
authors: F
authors: F
authors: Mungai
authors: R
authors: R
authors: Danesi
authors: F
authors: F
authors: Menichetti
authors: L
authors: L
authors: Dell'osso
authors: G B
authors: GB
authors: Cassano
mesh_terms: D000328:Adult; D000483:Alleles; D014150:Antipsychotic Agents / Q000009:adverse effects; D015283:Citalopram / Q000009:adverse effects; D017931:DNA Primers / Q000235:genetics; D003865:Major Depressive Disorder / Q000188:drug therapy; D006801:Humans; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology / Q000235:genetics*; D016133:Polymerase Chain Reaction; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D018967:Risperidone / Q000009:adverse effects; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects
chemical_list: D014150:Antipsychotic Agents; D015283:Citalopram; D017931:DNA Primers; D017448:Receptors, Dopamine D2; D018967:Risperidone; D017367:Selective Serotonin Reuptake Inhibitors